Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer
KTH, Skolan för kemi, bioteknologi och hälsa (CBH), Proteinvetenskap, Affinity Proteomics. KTH, Centra, Science for Life Laboratory, SciLifeLab.
KTH, Skolan för kemi, bioteknologi och hälsa (CBH), Proteinvetenskap, Affinity Proteomics.ORCID-id: 0000-0003-0880-5375
Visa övriga samt affilieringar
2018 (Engelska)Ingår i: Lung Cancer, ISSN 0169-5002, E-ISSN 1872-8332, Vol. 125, s. 157-163Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Objectives: Cancer-testis antigens (CTAs) are defined as proteins that are specifically expressed in testis or placenta and their expression is frequently activated in cancer. Due to their ability to induce an immune response, CTAs may serve as suitable targets for immunotherapy. The aim of this study was to evaluate if there is reactivity against CTAs in the plasma of non-small cell lung cancer (NSCLC) patients through the detection of circulating antibodies. Materials and methods: To comprehensively analyze autoantibodies against CTAs the multiplexing capacities of suspension bead array technology was used. Bead arrays were created with 120 protein fragments, representing 112 CTAs. Reactivity profiles were measured in plasma samples from 133 NSCLC patients and 57 cases with benign lung diseases. Results: Altogether reactivity against 69 antigens, representing 81 CTAs, was demonstrated in at least one of the analyzed samples. Twenty-nine of the antigens (45 CTAs) demonstrated exclusive reactivity in NSCLC samples. Reactivity against cancer-testis antigen family 47; member A (CT47A) genes, P antigen family member 3 (PAGE3), variable charge X-linked (VCX), melanoma antigen family B1 (MAGEB1), lin-28 homolog B (LIN28B) and chromosome 12 open reading frame 54 (C12orf54) were only found in NSCLC patients at a frequency of 1%–4%. The presence of autoantibodies towards these six antigens was confirmed in an independent group of 34 NSCLC patients. Conclusion: We identified autoantibodies against CTAs in the plasma of lung cancer patients. The reactivity pattern of autoantibodies was higher in cancer patients compared to the benign group, stable over time, but low in frequency of occurrence. The findings suggest that some CTAs are immunogenic and that these properties can be utilized as immune targets. 

Ort, förlag, år, upplaga, sidor
Elsevier Ireland Ltd , 2018. Vol. 125, s. 157-163
Nyckelord [en]
Adenocarcinoma, Cancer immunity, Lung cancer, MAGE, Squamous cell cancer, Tumor markers
Nationell ämneskategori
Klinisk medicin
Identifikatorer
URN: urn:nbn:se:kth:diva-236616DOI: 10.1016/j.lungcan.2018.09.012ISI: 000450378500023Scopus ID: 2-s2.0-85054035205OAI: oai:DiVA.org:kth-236616DiVA, id: diva2:1264017
Forskningsfinansiär
Science for Life Laboratory - a national resource center for high-throughput molecular bioscienceKnut och Alice Wallenbergs StiftelseCancerfonden, 2012/738
Anmärkning

Export Date: 22 October 2018; Article; CODEN: LUCAE; Correspondence Address: Djureinovic, D.; Department of Immunology, Genetics and Pathology, Uppsala UniversitySweden; email: dijana.djureinovic@igp.uu.se; Funding details: SciLifeLab, Science for Life Laboratory; Funding details: Knut och Alice Wallenbergs Stiftelse; Funding details: 2012/738, Cancerfonden; Funding text: This study was supported by the Swedish Cancer Society Cancerfonden (2012/738), Lions Cancer Foundation Uppsala, Sweden, Erik, Karin and Gösta Selanders Foundation, Sweden as well as grants for SciLifeLab and the Human Protein Atlas funded by the Knut and Alice Wallenberg foundation.; Funding text: We thank the Human Protein Atlas team, the Uppsala Biobank and everyone in the Division of Affinity Proteomics and the Autoimmunity Profiling facility at SciLifeLab for their support. Appendix A. QC 20181119

Tillgänglig från: 2018-11-19 Skapad: 2018-11-19 Senast uppdaterad: 2018-12-10Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextScopus

Personposter BETA

Dodig-Crnkovic, TeaHellström, CeciliaSchwenk, Jochen M.

Sök vidare i DiVA

Av författaren/redaktören
Dodig-Crnkovic, TeaHellström, CeciliaSchwenk, Jochen M.
Av organisationen
Affinity ProteomicsScience for Life Laboratory, SciLifeLab
I samma tidskrift
Lung Cancer
Klinisk medicin

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 255 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf